89bio, Inc. (ETNB) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 San Francisco, CA, 美国. 现任CEO为 Rohan Palekar.
ETNB 拥有 IPO日期为 2019-11-11, 93 名全职员工, 在 NASDAQ Global Market, 市值为 $2.2B.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
